Publications by authors named "Tatsuaki Sumiyoshi"
Objectives: To evaluate the effects of postoperative pancreatic enzyme replacement therapy on fat digestion and absorption in patients following initial total pancreatectomy.
Methods: Data were retrospectively collected from patients who underwent initial total pancreatectomy at our department between 2012 and 2020. Fat digestion, absorption functions, serum nutritional markers, HbA1c levels, and hepatic steatosis before and after the initial total pancreatectomy were evaluated.
Purpose: Pancreatic ductal adenocarcinoma (PDAC) patients with normal carbohydrate antigen (CA) 19-9 levels can have early-stage cancer or advanced cancer without elevation of CA19-9 level; estimating their malignant potential is difficult. This study investigated the clinical utility of the combined use of preoperative CA 19-9 and Duke pancreatic monoclonal antigen type 2 (DUPAN-2) levels in patients with PDAC.
Methods: Patients who underwent curative-intent surgery for PDAC between November 2005 and December 2021 were investigated.
Purpose: To elucidate the clinical significance of peritoneal washing cytology (PWC) in patients with resectable biliary tract cancer (BTC).
Methods: Clinical data of patients with BTC, who received PWC at curative intent surgery from March 2009 to December 2021, were retrospectively analyzed. Eligible patients were stratified into two groups according to positive or negative PWC.
Background/purpose: This study reports the long-term results of a phase II trial evaluating the clinical efficacy of neoadjuvant gemcitabine, nab-paclitaxel, and S1 (GAS) in borderline resectable pancreatic cancer with arterial contact (BRPC-A).
Methods: A multicenter, single-arm, phase II trial was conducted. Patients received six cycles of GAS and patients without progressive disease were intended for R0 resection.
Purpose: This study aimed to elucidate the difficulty of adjuvant chemotherapy administration in patients with biliary tract carcinoma (BTC).
Methods: Clinical data of patients with BTC who underwent curative-intent surgery were retrospectively analyzed. The eligible patients were stratified into two groups according to the presence or absence of adjuvant chemotherapy administration (adjuvant and non-adjuvant groups), and the clinicopathological features were compared between the two groups.
This study aimed to evaluate the optimal extent of lymphadenectomy in patients with nonfunctioning pancreatic neuroendocrine neoplasms. We retrospectively analyzed the clinicopathological data of patients with nonfunctioning pancreatic neuroendocrine neoplasms who underwent surgical resection. We investigated the frequency of metastases at each lymph node station according to tumor location and analyzed the factors contributing to poor overall survival (OS) and disease-free survival (DFS).
View Article and Find Full Text PDFObjective: To determine whether circulating microRNAs (miRNAs) can be used as prognostic biomarkers for pancreatic ductal adenocarcinoma (PDAC).
Methods: Patients with PDAC (N = 120) who underwent surgical resection at Hiroshima University Hospital between November 2006 and January 2020 were enrolled in this study and grouped based on their overall survival (OS) into two groups: favorable prognosis group (F group; OS ≥ 18 months) and unfavorable prognosis group (U group; OS < 18 months). Blood plasma samples were collected prior to surgery.
Prognostic factor in patient with recurrent pancreatic adenocarcinoma.
Langenbecks Arch Surg
September 2023
Purpose: To elucidate prognostic factors for post-recurrence survival in patients with pancreatic ductal adenocarcinoma (PDAC).
Methods: Patients who underwent curative-intent surgery for PDAC between January 2014 and May 2020 were identified. Among them, patients who had postoperative recurrences and received chemotherapy were retrospectively investigated.
Purpose: This study aimed to evaluate the prognostic impact of the initial recurrence site following resection for biliary tract carcinoma (BTC), focusing on lung recurrence.
Methods: The clinical data of patients with recurrent BTC who underwent curative intent surgery between March 2009 and December 2021 were retrospectively analyzed. The prognosis of patients with recurrent BTC was investigated in each recurrence site.
Purpose: This study aimed to evaluate the clinical significance of surgical resection for liver recurrence in patients with curatively resected pancreatic ductal adenocarcinoma.
Methods: The medical records of patients with a liver recurrence after undergoing curative pancreatectomy for pancreatic ductal adenocarcinoma were retrospectively reviewed. Clinicopathological and prognostic factors were analyzed, as was the clinical impact of surgical resection for liver recurrence.
Article Synopsis
- This study analyzed the safety and outcomes of surgeries involving hepatic artery resection (HAR) for patients with distal cholangiocarcinoma at Hiroshima University between 2009 and 2021.
- A total of 60 patients were reviewed, comparing those who underwent HAR to those who did not; findings showed more severe disease features in the HAR group, such as higher T stages and more lymph node metastasis.
- Results indicated that while HAR was performed safely with minimal complications, patients who had the procedure experienced significantly shorter disease-free survival times and were more likely to have early recurrences.
Article Synopsis
- A 47-year-old female with a history of BRCA1-related breast cancer was diagnosed with pancreatic ductal adenocarcinoma after experiencing back pain and high levels of a tumor marker, CA 19-9.
- After undergoing nine cycles of FOLFIRINOX chemotherapy, her tumor shrank significantly, and the metastases disappeared, leading to a switch to maintenance treatment with olaparib due to increased neuropathy.
- Following ten months of stable health, the patient underwent successful laparoscopic surgery, showing no signs of cancer in the removed tissue, and continued to do well without recurrence seven months post-surgery, highlighting the effectiveness of her treatment plan.
The standard chemotherapy for patients with unresectable cholangiocarcinoma is gemcitabine plus cisplatin, and gemcitabine plus S-1 (GS) chemotherapy is also reported to have similar effectiveness in Japan. However, the response rates of these two chemotherapies were modest, and no patients with intrahepatic cholangiocarcinoma (ICC) have shown a pathological complete response (pCR) following these chemotherapies. We report here the first case of an initially unresectable locally advanced ICC that achieved pCR following GS chemotherapy.
View Article and Find Full Text PDFAn aortic graft-duodenal fistula commonly requires graft replacement and duodenectomy. However, the appropriate surgical approach to the duodenum with aortic graft fistula remains unclear. Herein, we describe the case of an 85-year-old male patient who underwent a pancreas-preserving partial duodenectomy using the mesenteric approach for aortic graft-duodenal fistula.
View Article and Find Full Text PDFPurpose: Gastric cancer after pancreaticoduodenectomy was firstly reported in 1995, and the number of reports about this topic has increased in the past years. This review aimed to elucidate the clinicopathological features of this disease.
Methods: Data for 32 cases were obtained using literature search, and three cases in our institution were added.
Article Synopsis
- The study investigates preoperative risk factors for positive peritoneal lavage cytology (CY) specifically in patients with pancreatic ductal adenocarcinoma (PDAC) who underwent surgical resection, especially focusing on those who received neoadjuvant therapy.
- A total of 493 patients were analyzed, revealing that body and tail PDAC were significant risk factors for CY positivity in patients who did not receive neoadjuvant chemotherapy (NAC), while there were no predictive factors for those who did.
- The findings indicate that assessing the risk of CY positivity remains challenging, particularly in patients treated with NAC, which complicates determining the best indications for staging laparoscopy (SL).
Article Synopsis
- The study examined how the length of adjuvant gemcitabine plus S-1 (GS) chemotherapy affects survival rates in patients with pancreatic ductal adenocarcinoma (PDAC).
- Out of 290 patients, 100 had standard treatment (20-29 weeks) while 190 had extended treatment (30 weeks or more), with statistical methods used to minimize biases.
- Results indicated that those undergoing extended chemotherapy showed significantly better recurrence-free survival (RFS) and overall survival (OS), suggesting a need for further research on extended treatment benefits.*
Background/objectives: A disintegrin and metalloproteinase domain-containing protein 12 (ADAM12) has been reported to influence tumor progression and chemosensitivity in human cancers. We assessed the prognostic impact of ADAM12 and its predictive value for neoadjuvant chemotherapy (NAC) in patients with pancreatic ductal adenocarcinoma (PDAC) treated with surgical resection.
Methods: ADAM12 expression was immunohistochemically examined in 428 patients with PDAC who underwent surgical resection.
The long-term survival of patients with locally advanced, unresectable pancreatic cancer is extremely poor. We present our experience with a 67-year-old woman who had a 40-mm mass in the body of the pancreas. Tumor infiltration reached the gastroduodenal artery, celiac artery, common hepatic artery, and splenic artery.
View Article and Find Full Text PDFPurpose: The optimal range of lymph-node dissection for pancreatic tail cancer remains unclear. We investigated the location and frequency of lymph-node metastases to identify the correct range of lymph-node dissection for pancreatic tail cancer.
Methods: We analyzed clinical data retrospectively, on patients who underwent distal pancreatectomy for resectable left-sided pancreatic cancer, between February, 2006 and March, 2021.
Background: In recent trend of preoperative chemotherapy, postoperative clostridium difficile infection (CDI) might be increasing in pancreatic ductal adenocarcinoma (PDAC) patients. This study aimed to elucidate the inducement of postoperative CDI in the new era of preoperative chemotherapy.
Methods: Eligible patients were those who received pancreaticoduodenectomy for PDAC.
Article Synopsis
- The study investigates the effectiveness and safety of a neoadjuvant chemotherapy regimen (gemcitabine, nab-paclitaxel, and S-1) for patients with borderline resectable pancreatic cancer with arterial contact (BRPC-A), where effective preoperative treatment is crucial.
- Six cycles of treatment were administered to 47 patients, resulting in a 96% rate of potentially curative surgeries and an 86% R0 resection rate, indicating that the tumors were fully removed.
- The two-year overall survival rate was reported at 70.1%, with a median overall survival time of 41 months, demonstrating the regimen's good efficacy and manageable toxicity.
Introduction: The aim of this study was to identify preoperative risk factors for poor survival in patients with resectable pancreatic ductal adenocarcinoma (PDAC) treated with upfront surgery.
Methods: Medical records of 268 patients with resectable PDAC defined by resectability status who underwent upfront surgery were reviewed retrospectively. Multivariate analyses were performed to identify preoperative risk factors for recurrence-free survival (RFS) and overall survival (OS).
Neoadjuvant therapy contributes to nodal downstaging of pancreatic cancer.
Langenbecks Arch Surg
March 2022
Purpose: This study aimed to assess the impact of neoadjuvant therapy (NAT) for borderline resectable or locally advanced pancreatic cancer (BR/LAPC) on the American Joint Commission on Cancer (AJCC) nodal status.
Methods: The medical records of BR/LAPC patients who underwent surgery with curative intent were retrospectively reviewed. The nodal status was compared between patients who underwent upfront surgery (UFS) and those who received NAT.